 |
|
Alefacept for Alopecia Areata
Michael P. Heffernan, MD;
Maria Yadira Hurley, MD;
Kathleen S. Martin, BS;
David I. Smith, MD;
Milan J. Anadkat, MD
Division of Dermatology, Washington University School of Medicine (Drs Heffernan, Smith, and Anadkat), and Department of Dermatology, St Louis University School of Medicine (Dr Hurley), St Louis, Mo; and University of Missouri School of Medicine, Columbia (Ms Martin)
Arch Dermatol. 2005;141:1513-1516.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
REPORT OF CASES
Patient 1 is a 42-year-old white man who has had alopecia areata (AA) for 17 years. His father also has extensive AA. Early in the course of the disease, the patient intermittently received prednisone, 15 to 30 mg/d for 2 years, with 1 year being the longest duration of continuous treatment followed by an additional 7-month taper. The patient also received topical fluocinolone acetonide 0.1% (Synalar; Medicis, Scottsdale, Ariz) solution and intralesional triamcinolone acetonide (Kenalog; Bristol-Myers-Squibb, New York, NY) injections for most of the duration of the disease. He typically receives intralesional triamcinolone, 10 mg/mL to his scalp and 3 to 5 mg/mL to his eyebrows, every 4 to 10 weeks. Intralesional triamcinolone was helpful, with remissions lasting 2 months. Sulfasalazine administered failed secondary to drug eruption. He has never . . . [Full Text of this Article]
THERAPEUTIC CHALLENGE
SOLUTION
COMMENT
AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Alefacept for Severe Alopecia Areata: A Randomized, Double-blind, Placebo-Controlled Study
Strober et al.
Arch Dermatol 2009;145:1262-1266.
ABSTRACT
| FULL TEXT
|
